Showing results (1-10 of 35) with videos related to
Sort By:
Pageof 4
Immunotherapy|July 20, 2010
Immunotherapeutic strategies: the melanoma exampleAnnelies Jorritsma, Ton N M Schumacher, John B A G HaanenCurrent Gene Therapy|April 2, 2011
Prospects and limitations of T cell receptor gene therapyAnnelies Jorritsma, Remko Schotte, Miriam Coccoris, et al.Cancer Research|April 3, 2008
Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transferAnnelies Jorritsma, Adriaan D Bins, Ton N M Schumacher, et al.Human Gene Therapy|May 22, 2010
Microbead-assisted retroviral transduction for clinical applicationBianca Heemskerk, Annelies Jorritsma, Raquel Gomez-Eerland, et al.Pharmaceuticals (Basel, Switzerland)|September 28, 2021
Development and Characterisation of Antibody-Based Optical Imaging Probes for Inflammatory Bowel DiseaseMatthijs David Linssen, Wouter Tjerk Rudolph Hooghiemstra, Annelies Jorritsma-Smit, et al.Pharmaceutics|March 28, 2024
Optimization of the Production Process of Clinical-Grade Human Salivary Gland Organoid-Derived Cell Therapy for the Treatment of Radiation-Induced Xerostomia in Head and Neck CancerJacoba van Zanten, Annelies Jorritsma-Smit, Hans Westra, et al.Nature Medicine|June 21, 2005
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expressionAdriaan D Bins, Annelies Jorritsma, Monika C Wolkers, et al.Journal for Immunotherapy of Cancer|October 6, 2020
89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organsElly L van der Veen, Danique Giesen, Linda Pot-de Jong, et al.European Journal of Immunology|March 2, 2005
The carboxyl terminus of the chemokine receptor CCR3 contains distinct domains which regulate chemotactic signaling and receptor down-regulation in a ligand-dependent mannerIan Sabroe, Annelies Jorritsma, Victoria E L Stubbs, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2019
Roadmap for the Development and Clinical Translation of Optical Tracers Cetuximab-800CW and Trastuzumab-800CWMatthijs D Linssen, Eva J Ter Weele, Derk P Allersma, et al.Pageof 4